Data / Research funding / Florida / H. Lee Moffitt Cancer CTR & Res Inst
H. Lee Moffitt Cancer CTR & Res Inst: 193 NIH awards ($273.3M) and 5 NSF awards ($1.6M), fiscal years 2021 to 2026
H. Lee Moffitt Cancer CTR & Res Inst in Tampa, FL is funded under 193 NIH awards ($273.3M) and 5 NSF awards ($1.6M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- DVHKP4N619V9
- State
- Florida
Awards
198 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Moffitt Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $22,007,955 | February 18, 1998 | January 31, 2027 | CLEVELAND, JOHN L. | reporter.nih.gov |
| Identifying Metabolic Vulnerabilities in Lung Cancer | NIH | National Cancer Institute | 2021 to 2025 | $10,093,168 | June 25, 2021 | May 31, 2026 | FLORES, ELSA R | reporter.nih.gov |
| 2/2 Ponce Health Sciences University-Moffitt Cancer Center Partnership | NIH | National Cancer Institute | 2021 to 2025 | $6,478,218 | September 24, 2012 | August 31, 2028 | WRIGHT, KENNETH LYNN | reporter.nih.gov |
| The Delta Ecology of NSCLC Treatment | NIH | National Cancer Institute | 2023 to 2025 | $6,315,009 | September 15, 2023 | August 31, 2028 | ANDERSON, ALEXANDER ROBERTSON ALLAN | reporter.nih.gov |
| Quantitative Imaging Clinical Validation Center at Moffitt Cancer Center | NIH | National Cancer Institute | 2021 to 2025 | $3,928,528 | July 22, 2016 | August 31, 2028 | HEINE, JOHN J | reporter.nih.gov |
| HIV Genomic Aging Project in Oncology (HIV-GAP) | NIH | National Cancer Institute | 2021 to 2025 | $3,820,924 | September 20, 2021 | August 31, 2027 | COGHILL, ANNA | reporter.nih.gov |
| Advancing Clinical Trials: Working through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDERS) | NIH | National Cancer Institute | 2022 to 2025 | $3,673,561 | September 15, 2022 | August 31, 2027 | VADAPARAMPIL, SUSAN T | reporter.nih.gov |
| Using Radiogenomics to Noninvasively Predict the Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Uncover Hidden Biology | NIH | National Cancer Institute | 2021 to 2025 | $3,589,331 | July 1, 2019 | August 31, 2026 | PERMUTH, JENNIFER B | reporter.nih.gov |
| Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers | NIH | National Cancer Institute | 2021 to 2025 | $3,519,313 | July 12, 2021 | June 30, 2026 | DUCKETT, DEREK RONALD | reporter.nih.gov |
| Partnership to Assess Viral and Immune Landscape Intersections with ONcology for People Living with HIV (PAVILION) | NIH | National Cancer Institute | 2023 to 2025 | $3,426,827 | August 3, 2023 | July 31, 2028 | GIULIANO, ANNA R. | reporter.nih.gov |
| Radiomics and Pathomics to predict upstaging of DCIS | NIH | National Cancer Institute | 2021 to 2025 | $3,369,053 | May 1, 2021 | April 30, 2026 | NIELL, BETHANY LYNN | reporter.nih.gov |
| An Ionizing Radiation Acoustics Imaging (iRAI) Approach for guided Flash Radiotherapy | NIH | National Cancer Institute | 2022 to 2025 | $3,262,628 | September 20, 2022 | August 31, 2027 | EL NAQA, ISSAM M. | reporter.nih.gov |
| Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis | NIH | National Cancer Institute | 2021 to 2025 | $3,231,041 | August 9, 2021 | July 31, 2026 | SMALLEY, KEIRAN | reporter.nih.gov |
| Eco-evolutionary drivers of clonal dynamics during UV-induced skin carcinogenesis (PQ3) | NIH | National Cancer Institute | 2021 to 2025 | $3,142,500 | April 1, 2021 | March 31, 2027 | TSAI, KENNETH Y | reporter.nih.gov |
| Augmented Reality as an Adjunct to Quitline Counseling for Smoking Cessation | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,040,122 | July 1, 2022 | May 31, 2027 | VINCI, CHRISTINE | reporter.nih.gov |
| CARES-REACH (Colorectal Cancer Awareness, Research, Education and Screening-Rural Expansion, Access and Capacity for Health) | NIH | National Cancer Institute | 2021 to 2024 | $3,016,341 | April 1, 2020 | March 31, 2026 | GWEDE, CLEMENT K. | reporter.nih.gov |
| Trends and outcomes of lung cancer screening among people with and without HIV in the US | NIH | National Cancer Institute | 2025 | $2,991,283 | September 23, 2025 | August 31, 2029 | ISLAM, JESSICA YASMINE | reporter.nih.gov |
| Ending Tobacco Use through Interactive Tailored Messaging for Cambodian People Living with HIV/AIDS (EndIT) | NIH | National Cancer Institute | 2021 to 2025 | $2,979,791 | September 17, 2021 | August 31, 2027 | VIDRINE, DAMON J. | reporter.nih.gov |
| Modeling the role and regulation of reactive stroma in breast ductal carcinoma microinvasions | NIH | National Cancer Institute | 2022 to 2025 | $2,877,838 | September 1, 2022 | August 31, 2027 | REJNIAK, KATARZYNA ANNA | reporter.nih.gov |
| Efficacy of a Mindfulness-Based Stress Management Program for Allogeneic HCT Caregivers | NIH | National Cancer Institute | 2021 to 2025 | $2,839,105 | April 1, 2021 | March 31, 2027 | VINCI, CHRISTINE | reporter.nih.gov |
| Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison | NIH | National Cancer Institute | 2022 to 2025 | $2,766,745 | July 1, 2022 | June 30, 2027 | JIM, HEATHER S.L. | reporter.nih.gov |
| Imaging Acidosis and Immune Therapy in PDAC | NIH | National Cancer Institute | 2021 to 2024 | $2,672,496 | February 1, 2020 | January 31, 2026 | PILON-THOMAS, SHARI | reporter.nih.gov |
| Disrupting the Prostate Tumor Microenvironment in African American Men to Promote Response to Immuno-Modulatory Therapy | NIH | National Cancer Institute | 2022 to 2025 | $2,642,372 | September 1, 2022 | August 31, 2027 | YAMOAH, KOSJ | reporter.nih.gov |
| Improving weight loss outcomes of black women using a culturally relevant, stress management enhancement behavioral weight loss intervention | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,549,328 | April 1, 2021 | March 31, 2026 | CARSON, TIFFANY LASHAUN | reporter.nih.gov |
| AGING AS A SELECTIVE PRESSURE THAT DRIVES TUMOR PROGRESSION | NIH | National Institute on Aging | 2021 to 2024 | $2,472,750 | September 30, 2021 | June 30, 2026 | DA SILVA GOMES, ANA | reporter.nih.gov |
| Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,411,491 | August 12, 2019 | July 31, 2026 | PADRON, ERIC | reporter.nih.gov |
| Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,331,598 | April 1, 2021 | March 31, 2027 | REJNIAK, KATARZYNA ANNA | reporter.nih.gov |
| Partnering with a State Food Bank to Provide Tobacco Treatment to Underserved Smokers | NIH | National Cancer Institute | 2021 to 2024 | $2,315,994 | September 7, 2019 | November 30, 2025 | VIDRINE, DAMON J. | reporter.nih.gov |
| Chromosome 1q ceRNAs in Melanoma Progression and Metastasis | NIH | National Cancer Institute | 2021 to 2025 | $2,273,687 | May 1, 2021 | April 30, 2027 | KARRETH, FLORIAN | reporter.nih.gov |
| New reagents for C-C and C-N bond formation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,203,498 | July 1, 2021 | April 30, 2026 | LOPCHUK, JUSTIN MATTHEW | reporter.nih.gov |
| New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,168,990 | June 1, 2020 | May 31, 2025 | CLEVELAND, JOHN L. | reporter.nih.gov |
| Biophysical basis for enzyme mediated deglycation in protein repair | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,168,147 | June 1, 2021 | March 31, 2026 | BINNING, JENNIFER | reporter.nih.gov |
| Oral HPV Research Among Latin Americans Living with HIV (ORAL - H² Study) | NIH | National Cancer Institute | 2022 to 2025 | $2,160,881 | September 12, 2022 | August 31, 2028 | GIULIANO, ANNA R. | reporter.nih.gov |
| Therapeutic Targeting of Casein Kinase-1-delta in Primary and Metastatic Breast Cancer | NIH | National Cancer Institute | 2021 to 2023 | $2,159,273 | June 4, 2018 | November 30, 2023 | DUCKETT, DEREK RONALD | reporter.nih.gov |
| Biomarker Approach to Screening for the early detection of HPV-related Oropharyngeal Cancer (BASH OPC) | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2025 | $2,145,712 | September 4, 2023 | June 30, 2028 | GIULIANO, ANNA R. | reporter.nih.gov |
| Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers | NIH | National Cancer Institute | 2021 to 2023 | $2,114,438 | May 15, 2018 | November 30, 2024 | DUCKETT, DEREK RONALD | reporter.nih.gov |
| Characterizing cytotoxic therapy induced shifts in the cost-to-benefit ratio of high ploidy | NIH | National Cancer Institute | 2022 to 2025 | $2,095,115 | September 1, 2022 | August 31, 2027 | ANDOR, NOEMI | reporter.nih.gov |
| Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds | NIH | National Cancer Institute | 2021 to 2025 | $2,060,474 | September 15, 2021 | August 31, 2027 | RODRIGUEZ, PAULO CESAR | reporter.nih.gov |
| Novel Therapy to Inhibit IPMN Progression | NIH | National Cancer Institute | 2022 to 2024 | $2,052,249 | June 8, 2022 | May 31, 2027 | MALAFA, MOKENGE P. | reporter.nih.gov |
| Tampa Bay Life Sciences Computing Commons (TBLSCC) | NIH | Office of the Director, National Institutes of Health | 2022 | $1,999,814 | May 15, 2022 | May 14, 2025 | ESCHRICH, STEVEN ALLEN | reporter.nih.gov |
| Role of CRTC1-MAML2 in Salivary Mucoepidermoid Carcinoma Pathobiology | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $1,985,114 | December 2, 2022 | April 30, 2027 | AMELIO, ANTONIO LUIGI | reporter.nih.gov |
| Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,946,461 | September 1, 2019 | January 31, 2030 | LUCA, VINCENT CHRISTOPHER | reporter.nih.gov |
| Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $1,944,040 | March 1, 2020 | February 28, 2025 | DUCKETT, DEREK RONALD | reporter.nih.gov |
| Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,926,403 | January 1, 2023 | December 31, 2027 | PERES, LAUREN COLE | reporter.nih.gov |
| Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma | NIH | National Cancer Institute | 2022 to 2025 | $1,926,244 | July 15, 2022 | June 30, 2027 | SMALLEY, KEIRAN | reporter.nih.gov |
| Combined radiation acoustics and ultrasound imaging for real-time guidance in radiotherapy | NIH | National Cancer Institute | 2021 to 2024 | $1,923,937 | August 1, 2023 | July 31, 2025 | EL NAQA, ISSAM M. | reporter.nih.gov |
| Targeting altered phosphatase-dependent signaling to overcome the inefficacy of targeted therapy in myeloproliferative neoplasms | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,911,360 | February 15, 2021 | January 31, 2026 | REUTHER, GARY W | reporter.nih.gov |
| Randomized Trial of Automated Video-Assisted Smoking Treatment for People Living with HIV | NIH | National Cancer Institute | 2021 to 2024 | $1,907,795 | September 19, 2019 | August 31, 2025 | VIDRINE, DAMON J. | reporter.nih.gov |
| Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors | NIH | National Cancer Institute | 2022 to 2025 | $1,900,239 | September 1, 2022 | August 31, 2027 | RODRIGUEZ, PAULO CESAR | reporter.nih.gov |
| Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on γδ T cells, in the bone microenvironment. | NIH | National Cancer Institute | 2021 to 2024 | $1,866,870 | March 9, 2020 | August 31, 2025 | ABATE-DAGA, DANIEL | reporter.nih.gov |
| Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma | NIH | National Cancer Institute | 2021 to 2022 | $1,840,537 | September 1, 2016 | March 31, 2024 | FLORES, ELSA R | reporter.nih.gov |
| Identifying and Reducing Disparities in Patient-Reported Outcomes Among African American Prostate Cancer Survivors | NIH | National Cancer Institute | 2021 to 2024 | $1,806,535 | July 23, 2020 | June 30, 2026 | GONZALEZ, BRIAN D | reporter.nih.gov |
| Phase II Clinical trial of GTC in Men on Active Surveillance | NIH | National Cancer Institute | 2021 to 2024 | $1,792,639 | June 1, 2019 | May 31, 2026 | KUMAR, NAGI B. | reporter.nih.gov |
| Defining bone ecosystem effects on metastatic prostate cancer evolution and treatment response using an integrated mathematical modeling approach | NIH | National Cancer Institute | 2021 to 2024 | $1,758,201 | June 11, 2020 | May 31, 2025 | LYNCH, CONOR C | reporter.nih.gov |
| Anti-tumor potential of temperature-sensitive p53 mutants | NIH | National Cancer Institute | 2021 to 2025 | $1,747,237 | March 1, 2021 | February 28, 2027 | CHEN, JIANDONG | reporter.nih.gov |
| The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia | NIH | National Cancer Institute | 2023 to 2025 | $1,725,494 | March 7, 2023 | February 29, 2028 | PADRON, ERIC | reporter.nih.gov |
| CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,710,401 | August 1, 2020 | April 30, 2026 | KISSIL, JOSEPH | reporter.nih.gov |
| Developing a Cancer Galaxy Computational Workbench to Meet Emerging Cancer Data Analysis Needs | NIH | National Cancer Institute | 2024 to 2025 | $1,704,339 | September 1, 2024 | August 31, 2029 | GOECKS, JEREMY | reporter.nih.gov |
| Elucidating the epigenetic landscape of neurofibromatosis and development of therapeutic targets | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,671,259 | September 1, 2021 | August 31, 2025 | KISSIL, JOSEPH | reporter.nih.gov |
| Behavioral Oncology Education & Career Development | NIH | National Cancer Institute | 2021 to 2025 | $1,625,411 | September 11, 2019 | August 31, 2029 | VADAPARAMPIL, SUSAN T | reporter.nih.gov |
| Role of ULK3 in Sensitive and Refractory Multiple Myeloma | NIH | National Cancer Institute | 2023 to 2025 | $1,580,551 | December 16, 2022 | November 30, 2027 | LYNCH, CONOR C | reporter.nih.gov |
| Optimal Decision Making in Radiotherapy Using Panomics Analytics | NIH | National Cancer Institute | 2021 to 2023 | $1,536,845 | June 6, 2019 | May 31, 2025 | EL NAQA, ISSAM M. | reporter.nih.gov |
| Investigation of NRF2-Dependent Metabolic Liabilities | NIH | National Cancer Institute | 2021 to 2024 | $1,529,193 | July 1, 2023 | June 30, 2025 | DENICOLA, GINA MARIE | reporter.nih.gov |
| Characterizing oncogenic function of ITCH in melanoma | NIH | National Cancer Institute | 2021 to 2025 | $1,491,935 | August 1, 2021 | July 31, 2027 | WAN, LIXIN | reporter.nih.gov |
| Determining the structural- and functional-level effects of diet-specific interventions on the gut microbiota of a diverse sample of Southern United States adults | NIH | National Cancer Institute | 2021 to 2025 | $1,479,557 | June 1, 2021 | May 31, 2026 | CARSON, TIFFANY LASHAUN | reporter.nih.gov |
| Study of Anti-Tumor Immunity and Tissue Resident Memory Cell Development by NKG2D and Ribosomal Protein S6 Signaling in T cells | NIH | National Cancer Institute | 2021 to 2024 | $1,441,104 | July 14, 2021 | February 28, 2025 | GUEVARA-PATINO, JOSE ALEJANDRO | reporter.nih.gov |
| IGF::OT::IGF THE NATIONAL MYELODYSPLASTIC SYNDROMES (MDS) NATURAL HISTORY STUDY, CENTRAL LAB AND BIOREPOSITORY (CLB), TASK ORDER 03, SEPTEMBER 1, 2016-FEBRUARY 28, 2018 | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $1,409,305 | September 1, 2016 | March 31, 2025 | BURNETTE, PEARLIE K | reporter.nih.gov |
| B cell-dependent anti-tumor immunity in ovarian cancer | NIH | National Cancer Institute | 2021 to 2022 | $1,407,712 | September 20, 2018 | January 29, 2023 | CONEJO-GARCIA, JOSE R | reporter.nih.gov |
| Role of Bcl11b in CD4+ T cells and innate lymphoid cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,395,330 | September 16, 2007 | June 30, 2024 | AVRAM, DORINA | reporter.nih.gov |
| Body composition and adiposity-associated thromboinflammation in colorectal cancer prognosis | NIH | National Cancer Institute | 2024 to 2025 | $1,388,285 | May 1, 2024 | April 30, 2028 | BYRD, DORATHA ARMENTHUS | reporter.nih.gov |
| A hybrid effectiveness-implementation trial to integrate precision skin cancer risk feedback in federally qualified health centers | NIH | National Cancer Institute | 2024 to 2025 | $1,381,782 | September 1, 2024 | August 31, 2029 | KANETSKY, PETER A | reporter.nih.gov |
| Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy | NIH | National Cancer Institute | 2024 to 2025 | $1,381,378 | August 1, 2024 | July 31, 2029 | OSWALD, LAURA B. | reporter.nih.gov |
| Allosteric Regulation of MDMX by Protein Disorder | NIH | National Cancer Institute | 2022 to 2025 | $1,380,886 | September 1, 2009 | December 31, 2026 | CHEN, JIANDONG | reporter.nih.gov |
| RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing | NIH | National Cancer Institute | 2023 to 2025 | $1,370,948 | April 15, 2023 | March 31, 2028 | MANN, KAREN M | reporter.nih.gov |
| Impact of Targeted Therapy on Cancer-Related Cognitive Impairment | NIH | National Cancer Institute | 2024 to 2025 | $1,364,661 | September 1, 2024 | August 31, 2029 | GONZALEZ, BRIAN D | reporter.nih.gov |
| Improving Prediction of Chemotherapy-Induced Nausea: Integrating Genes, Behavior, and the Microbiome | NIH | National Cancer Institute | 2021 to 2022 | $1,361,529 | June 1, 2018 | May 31, 2025 | JIM, HEATHER S.L. | reporter.nih.gov |
| Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance | NIH | National Cancer Institute | 2021 to 2022 | $1,348,427 | September 19, 2018 | August 31, 2023 | ANDERSON, ALEXANDER ROBERTSON ALLAN | reporter.nih.gov |
| Direct Control of the human CMG Helicase by Myc and Rb | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,317,600 | June 1, 2021 | November 30, 2025 | ALEXANDROW, MARK G. | reporter.nih.gov |
| Local and systemic control of multiple myeloma colonization and growth by MMP-13 | NIH | National Cancer Institute | 2021 to 2023 | $1,303,699 | March 1, 2019 | February 28, 2025 | LYNCH, CONOR C | reporter.nih.gov |
| Selective targeting of TAF1 function in acute myeloid leukemia | NIH | National Cancer Institute | 2024 to 2025 | $1,271,248 | February 16, 2024 | January 31, 2029 | SCHONBRUNN, ERNST | reporter.nih.gov |
| A High Content Screening Platform for High Throughput, High Content Imaging and Analysis | NIH | Office of the Director, National Institutes of Health | 2022 | $1,254,909 | September 20, 2022 | September 19, 2023 | MCDONALD, PATRICIA HELEN | reporter.nih.gov |
| Epigenetic and metabolic bottlenecks of tumorigenesis | NIH | National Cancer Institute | 2024 to 2025 | $1,238,678 | July 3, 2024 | June 30, 2026 | DA SILVA GOMES, ANA | reporter.nih.gov |
| Enhancing TIL populations and immunotherapy efficacy in melanoma by modulating fucosylation | NIH | National Cancer Institute | 2021 to 2023 | $1,229,023 | June 1, 2019 | May 31, 2025 | LAU, ERIC KIRK | reporter.nih.gov |
| Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy | NIH | National Cancer Institute | 2021 to 2023 | $1,219,957 | March 1, 2020 | August 31, 2023 | ENDERLING, HEIKO | reporter.nih.gov |
| Analytical tools for studying the tumor microenvironment leveraging spatial transcriptomics | NIH | National Cancer Institute | 2022 to 2024 | $1,218,831 | September 1, 2022 | August 31, 2025 | YU, XIAOQING | reporter.nih.gov |
| Investigating the prognostic role of intrinsic immune evasion mechanisms in HNSCC | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2023 | $1,182,792 | April 1, 2021 | March 31, 2024 | WANG, XUEFENG | reporter.nih.gov |
| Randomized Placebo Controlled Trial of Bupropion for Cancer Related Fatigue | NIH | National Cancer Institute | 2021 to 2022 | $1,173,056 | June 12, 2018 | May 31, 2025 | JIM, HEATHER S.L. | reporter.nih.gov |
| Regulation of dendritic cell function and tumor immunity by TIM-3 | NIH | National Cancer Institute | 2021 to 2023 | $1,172,481 | September 16, 2019 | August 31, 2024 | RUFFELL, BRIAN | reporter.nih.gov |
| Dual Source Ion Mobility-Mass Spectrometer | NIH | Office of the Director, National Institutes of Health | 2022 | $1,167,628 | May 1, 2022 | April 30, 2023 | KOOMEN, JOHN M | reporter.nih.gov |
| Integrated Program in Cancer and Data Science | NIH | National Cancer Institute | 2021 to 2023 | $1,166,708 | September 16, 2019 | August 31, 2025 | CRESS, WILLIAM DOUGLAS | reporter.nih.gov |
| A Stepped-care Psychosocial Intervention for Brain Tumor Family Caregivers | NIH | National Cancer Institute | 2021 to 2023 | $1,165,108 | July 1, 2019 | June 30, 2025 | BYRNE, MARGARET M | reporter.nih.gov |
| Functional reprogramming of tumor-MDSC through antibody-based therapies targeting Notch ligands | NIH | National Cancer Institute | 2021 to 2023 | $1,164,612 | June 6, 2019 | May 31, 2024 | RODRIGUEZ, PAULO CESAR | reporter.nih.gov |
| Cell free nucleic acid-based biomarkers in advanced prostate cancer | NIH | National Cancer Institute | 2021 to 2022 | $1,162,841 | August 1, 2017 | January 31, 2025 | WANG, LIANG | reporter.nih.gov |
| Functional characterization of prostate cancer risk loci by high throughput sequencing | NIH | National Cancer Institute | 2021 to 2023 | $1,112,470 | July 1, 2020 | June 30, 2025 | WANG, LIANG | reporter.nih.gov |
| MYC-alarmin axis as a novel therapeutic vulnerability in myelofibrosis | NIH | National Cancer Institute | 2024 to 2025 | $1,106,082 | June 1, 2024 | May 31, 2026 | YUN, SEONGSEOK | reporter.nih.gov |
| Targeting Malignant Reprogramming of Glioblastoma Stem Cells Through Dual Inhibition of S6K1 and BIRC3 | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,091,011 | December 19, 2023 | November 30, 2028 | ETAME, ARNOLD | reporter.nih.gov |
| Ghana IntegRative Approach to Cancer ResEarch Training: The Grace Program | NIH | National Cancer Institute | 2021 to 2025 | $1,087,889 | May 19, 2021 | April 30, 2027 | YAMOAH, KOSJ | reporter.nih.gov |
| Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma | NIH | National Cancer Institute | 2021 to 2022 | $1,086,087 | July 2, 2019 | January 29, 2023 | CONEJO-GARCIA, JOSE R | reporter.nih.gov |
| Developing chemical probes for oncogenic signaling pathways | NIH | National Cancer Institute | 2021 to 2025 | $1,079,413 | September 19, 2017 | August 31, 2028 | LAWRENCE, HARSHANI R | reporter.nih.gov |
| Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers - UG1 | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,047,558 | August 8, 2011 | June 30, 2031 | PIDALA, JOSEPH A | reporter.nih.gov |
| Identifying cell surface targets for innovative immunotherapy of Multiple Myeloma | NIH | National Cancer Institute | 2024 to 2025 | $1,035,372 | July 1, 2024 | June 30, 2029 | PERNA, FABIANA | reporter.nih.gov |
| Leveraging the Lymphocytic Infiltration of Soft Tissue Sarcoma for Autologous Cellular Immunotherapy | NIH | National Cancer Institute | 2021 to 2024 | $981,184 | August 1, 2020 | July 31, 2025 | MULLINAX, JOHN | reporter.nih.gov |
| Interrogating the relationship between translational dynamics and non-canonical antigen presentation in lung cancer | NIH | National Cancer Institute | 2024 to 2025 | $970,988 | July 15, 2024 | June 30, 2026 | JAEGER, ALEX | reporter.nih.gov |
| Role of Sirt2 in T Cell Metabolism | NIH | National Cancer Institute | 2021 to 2023 | $945,113 | March 1, 2021 | June 18, 2023 | KIM, SUNGJUNE | reporter.nih.gov |
| Defining impact of in situ activation of CD40 and type 1 interferon signaling on theTME and systemic T cell immunity in murine models and cancer patients | NIH | National Cancer Institute | 2024 to 2025 | $920,408 | May 1, 2024 | April 30, 2029 | BEG, AMER AZIZ | reporter.nih.gov |
| Harnessing big data to understand the confluence of HIV and cancer stigma in the US Southeast | NIH | National Cancer Institute | 2025 | $851,463 | September 1, 2025 | August 31, 2030 | ISLAM, JESSICA YASMINE | reporter.nih.gov |
| Dissecting enhancer function through integrative genomics | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $842,500 | September 5, 2024 | July 31, 2029 | TENG, MINGXIANG | reporter.nih.gov |
| Employing functionalized fragment libraries to identify therapeutic agents for neurofibromatosis type 2 | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $827,108 | January 1, 2021 | December 31, 2025 | KISSIL, JOSEPH | reporter.nih.gov |
| Role of the Chromosome 19 MicroRNA Cluster in Liver Cancers | NIH | National Cancer Institute | 2021 to 2023 | $746,439 | August 12, 2021 | January 31, 2025 | BROHL, ANDREW SCOTT | reporter.nih.gov |
| Targeting antioxidant vulnerabilities in KEAP1/NRF2 mutant NSCLC | NIH | National Cancer Institute | 2023 to 2025 | $746,153 | September 1, 2022 | August 31, 2026 | JIANG, CHANG | reporter.nih.gov |
| Exploring the impact of HSP90 inhibition on antigen presentation and anti-tumor immune responses | NIH | National Cancer Institute | 2022 to 2024 | $742,016 | March 2, 2020 | February 28, 2025 | JAEGER, ALEX | reporter.nih.gov |
| Aging, DNA methylation, and incident cardiovascular disease in breast cancer survivors | NIH | National Cancer Institute | 2025 | $734,942 | August 1, 2025 | July 31, 2030 | KRESOVICH, JACOB K | reporter.nih.gov |
| Regulatory Dendritic Cells in Cancer | NIH | National Cancer Institute | 2021 to 2022 | $727,947 | July 1, 2007 | February 28, 2023 | CONEJO-GARCIA, JOSE R | reporter.nih.gov |
| Finding Synergy with Radiation Therapy and Immunotherapy for Patients with Lung Cancer | NIH | National Cancer Institute | 2021 to 2023 | $716,256 | August 1, 2019 | December 22, 2023 | PEREZ, BRADFORD A. | reporter.nih.gov |
| Ultrasensitive detection of circulating DNA methylation for head and neck cancer prognosis | NIH | National Institute of Dental & Craniofacial Research | 2025 | $716,123 | September 8, 2025 | May 31, 2030 | CHUNG, CHRISTINE H | reporter.nih.gov |
| The MIND-BC Study: MIND diet for Breast cancer Cognition | NIH | National Cancer Institute | 2025 | $713,235 | April 1, 2025 | March 31, 2030 | CROWDER, SYLVIA | reporter.nih.gov |
| Investigation of Oral HPV Infection Natural History and Biomarkers of Persistent Infection: The HIM Study | NIH | National Cancer Institute | 2021 | $711,793 | March 21, 2017 | February 29, 2024 | GIULIANO, ANNA R. | reporter.nih.gov |
| Nitric oxide immune dependent resistance mechanisms to anti-PD-1 therapy | NIH | National Cancer Institute | 2021 to 2023 | $707,478 | September 1, 2021 | December 31, 2024 | MARKOWITZ, JOSEPH | reporter.nih.gov |
| Decoding tobacco-related oral cancer ecosystem by integrative approach | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2022 | $672,996 | September 1, 2021 | September 30, 2022 | TAN, AIK CHOON | reporter.nih.gov |
| Vitamin B12 supplementation as novel therapeutic strategy to improve cancer-associated outcomes | NIH | National Cancer Institute | 2021 to 2022 | $666,500 | September 10, 2020 | August 31, 2023 | DA SILVA GOMES, ANA | reporter.nih.gov |
| Discovery and verification of methylated circulating tumor DNA markers for the detection of colorectal cancer in subjects under 50 years of age | NIH | National Cancer Institute | 2025 | $663,923 | July 1, 2021 | June 30, 2027 | HITCHINS, MEGAN P | reporter.nih.gov |
| Remodeling the Immune Landscape in Breast Cancer Leptomeningeal Disease Using Dendritic Cell Therapy is an Effective Treatment and Protects Against Disease Recurrence. | NIH | National Cancer Institute | 2025 | $657,121 | December 12, 2024 | November 30, 2029 | FORSYTH, PETER ALEXANDER | reporter.nih.gov |
| Tumor suppressor roles of TFEB in the development and maintenance of myeloid leukemia | NIH | National Cancer Institute | 2021 to 2023 | $650,375 | September 11, 2019 | August 31, 2024 | YUN, SEONGSEOK | reporter.nih.gov |
| Adaptation and Preliminary Evaluation of Energize-MBC: Cognitive Behavioral Therapy for Fatigue among Women with Metastatic Breast Cancer | NIH | National Cancer Institute | 2024 to 2025 | $627,562 | September 18, 2024 | August 31, 2027 | JIM, HEATHER S.L. | reporter.nih.gov |
| An integrated mathematical modeling approach to define how the aging bone ecosystem drives multiple myeloma evolution and treatment response | NIH | National Cancer Institute | 2025 | $620,521 | January 1, 2025 | December 31, 2029 | LYNCH, CONOR C | reporter.nih.gov |
| A redox-sensitive switch in the macrophage nucleus regulates acute phaseinflammatory injury | NIH | National Heart, Lung, and Blood Institute | 2025 | $613,814 | June 1, 2022 | May 31, 2027 | BONINI, MARCELO G. | reporter.nih.gov |
| Release of interleukin-1a as a mediator of immune evasion in cancer | NIH | National Cancer Institute | 2025 | $568,538 | December 10, 2024 | November 30, 2029 | RUFFELL, BRIAN | reporter.nih.gov |
| Structure-function studies of LAG3 interactions with antibodies and cellular ligands | NIH | National Cancer Institute | 2025 | $549,962 | April 1, 2025 | March 31, 2030 | LUCA, VINCENT CHRISTOPHER | reporter.nih.gov |
| Program control of CD8+ T cell response to tumors and tumor memory | NIH | National Cancer Institute | 2025 | $549,460 | August 13, 2025 | April 30, 2030 | AVRAM, DORINA | reporter.nih.gov |
| IMAT-ITCR Collaboration: Engineering model-based systems to monitor and steer subclonal dynamics | NIH | National Cancer Institute | 2023 to 2024 | $499,193 | September 1, 2024 | April 30, 2026 | ANDOR, NOEMI | reporter.nih.gov |
| Defining the Role of Metabolic Heterogeneity in Melanoma Dissemination and Therapy Escape | NIH | National Cancer Institute | 2021 to 2022 | $498,000 | September 1, 2020 | August 31, 2024 | SMALLEY, INNA | reporter.nih.gov |
| Alternatively spliced cell surface proteins as drivers of leukemogenesis and targets for immunotherapy | NIH | National Cancer Institute | 2023 to 2024 | $490,583 | August 1, 2023 | July 31, 2025 | PERNA, FABIANA | reporter.nih.gov |
| Tele-resistance training during chemotherapy for advanced upper gastrointestinal cancer | NIH | National Cancer Institute | 2022 to 2024 | $482,679 | March 15, 2022 | February 28, 2026 | PARKER, NATHAN H | reporter.nih.gov |
| Suppression of progesterone receptor signaling by heavy metals promotes tamoxifen resistance and metastasis or ER+ breast cancer | NIH | National Institute of Environmental Health Sciences | 2025 | $480,442 | June 24, 2024 | March 31, 2030 | BONINI, MARCELO G. | reporter.nih.gov |
| Targeting bidirectional signaling in lung stroma and cancer cells | NIH | National Cancer Institute | 2021 | $478,243 | August 1, 2017 | July 31, 2023 | RIX, UWE | reporter.nih.gov |
| Novel role of melanin-carbonyls in progression of NRAS mutant melanoma | NIH | National Institute of Environmental Health Sciences | 2023 | $463,375 | July 22, 2023 | June 30, 2025 | PREMI, SANJAY | reporter.nih.gov |
| Adaptations of breast cancer metastasis to the aging lung | NIH | National Institute on Aging | 2023 to 2024 | $463,375 | September 1, 2023 | May 31, 2026 | DA SILVA GOMES, ANA | reporter.nih.gov |
| Diazirines and Diaziridines as Nitrogen Transfer Reagents | NSF | Chemistry Section | 2023 | $450,000 | August 1, 2023 | July 31, 2026 | Justin M Lopchuk | nsf.gov |
| Development of Diazirine-based Amination Reactions | NSF | Chemistry Section | 2026 | $450,000 | August 1, 2026 | July 31, 2029 | Justin M Lopchuk | nsf.gov |
| Validation of EGFR Protein Complexes as Molecular Diagnostics | NIH | National Cancer Institute | 2021 to 2022 | $447,397 | September 6, 2016 | June 30, 2024 | HAURA, ERIC B. | reporter.nih.gov |
| SCenE - Self-Assessment and Continual Learning on Edge Devices | NSF | Office of Advanced Cyberinfrastructure (OAC) | 2023 | $434,030 | October 1, 2022 | September 30, 2025 | Ghulam Rasool | nsf.gov |
| Exploiting Epigenetic Vulnerabilities In Glioblastoma Stem Cells Through Reprogramming | NIH | National Cancer Institute | 2022 | $433,257 | September 23, 2022 | August 31, 2024 | ETAME, ARNOLD | reporter.nih.gov |
| Overcoming resistance to KRAS inhibitors through a fragment-based chemoproteomics approach | NIH | National Cancer Institute | 2023 | $433,256 | September 19, 2023 | August 31, 2025 | HAURA, ERIC B. | reporter.nih.gov |
| Targeting a PHGDH metabolic vulnerability in melanoma | NIH | National Cancer Institute | 2024 | $433,256 | May 16, 2024 | April 30, 2026 | KARRETH, FLORIAN | reporter.nih.gov |
| Exploring anti-sense RNAs in melanocyte transformation and melanoma formation | NIH | National Cancer Institute | 2025 | $433,256 | September 1, 2025 | August 31, 2027 | KARRETH, FLORIAN | reporter.nih.gov |
| Development of adverse event (AE) derived biomarkers for predicting clinical outcomes in lung cancer | NIH | National Cancer Institute | 2024 to 2025 | $433,255 | January 12, 2024 | December 31, 2026 | CHEN, DUNG-TSA | reporter.nih.gov |
| Development of bifunctional CDK2 inhibitors for treatment of CCNE1-driven cancers | NIH | National Cancer Institute | 2024 to 2025 | $433,255 | April 1, 2024 | March 31, 2026 | SCHONBRUNN, ERNST | reporter.nih.gov |
| Defining and targeting the epigenetic programs involved in melanoma development | NIH | National Cancer Institute | 2022 to 2023 | $429,318 | January 1, 2022 | December 31, 2024 | SMALLEY, KEIRAN | reporter.nih.gov |
| Characterization of the oncogenic potential of circRNAs in melanoma | NIH | National Cancer Institute | 2022 to 2023 | $429,318 | January 1, 2022 | December 31, 2023 | KARRETH, FLORIAN | reporter.nih.gov |
| Molecular Drivers of Lung Cancer in Hispanics | NIH | National Cancer Institute | 2022 to 2023 | $429,318 | January 1, 2022 | December 31, 2024 | CRESS, WILLIAM DOUGLAS | reporter.nih.gov |
| Defining and targeting the immune-suppressive metabolic microenvironment of leptomeningeal melanoma metastases | NIH | National Cancer Institute | 2022 to 2023 | $429,318 | September 1, 2022 | February 28, 2025 | SMALLEY, INNA | reporter.nih.gov |
| The ODC A allele as a driver and therapeutic target of aggressive prostate cancer in African American men | NIH | National Cancer Institute | 2022 to 2023 | $428,529 | February 2, 2022 | January 31, 2026 | PARK, JONG Y. | reporter.nih.gov |
| Epidemiologic study of microplastic pollution in bronchoalveolar lavage fluid and its association with lung cancer | NIH | National Cancer Institute | 2024 | $425,772 | July 15, 2024 | June 30, 2026 | EGAN, KATHLEEN M. | reporter.nih.gov |
| Dissecting the immunological mechanisms associated with prostate cancer progression in African-American men and exploring epigenetics-based immune modulation for therapy | NIH | National Cancer Institute | 2021 | $423,486 | May 1, 2021 | January 27, 2023 | ADEEGBE, DENNIS O | reporter.nih.gov |
| The influence of extreme weather events on emergency department utilization among cancer patients in Florida | NIH | National Cancer Institute | 2025 | $423,462 | August 1, 2025 | July 31, 2027 | KRESOVICH, JACOB K | reporter.nih.gov |
| Developing GRB2-PROTACs for Treatment of Lung Cancer | NIH | National Cancer Institute | 2023 to 2024 | $423,408 | December 9, 2022 | November 30, 2024 | JI, HAITAO MARK | reporter.nih.gov |
| Integrated fragment-based phenotypic screening and chemoproteomics for identification of novel small cell lung cancer-specific targets | NIH | National Cancer Institute | 2023 to 2024 | $423,408 | February 2, 2023 | March 31, 2025 | RIX, UWE | reporter.nih.gov |
| KIR2DL2 Immune Checkpoint as Modulator of T-Cell Effector Function | NIH | National Cancer Institute | 2023 to 2024 | $421,440 | April 1, 2023 | March 31, 2026 | ABATE-DAGA, DANIEL | reporter.nih.gov |
| RESISTANCE AND RESPONSE SIGNALING TO PARP1 INHIBITORS IN OVARIAN CANCER | NIH | National Cancer Institute | 2021 to 2022 | $419,636 | February 1, 2021 | January 31, 2024 | MONTEIRO, ALVARO N | reporter.nih.gov |
| Developing mathematical model driven optimized recurrent glioblastoma therapies | NIH | National Cancer Institute | 2021 to 2022 | $419,636 | July 1, 2021 | June 30, 2024 | YU, HSIANG-HSUAN MICHAEL | reporter.nih.gov |
| Targeting the suppressive immune microenvironment in leptomeningeal melanoma metastases | NIH | National Cancer Institute | 2021 to 2022 | $419,636 | August 1, 2021 | July 31, 2023 | SMALLEY, KEIRAN | reporter.nih.gov |
| Exploring miR-29 in melanoma progression and prevention | NIH | National Cancer Institute | 2021 to 2022 | $418,865 | August 1, 2021 | April 30, 2024 | KARRETH, FLORIAN | reporter.nih.gov |
| Exploratory Study of T Cell Skin Trafficking and the Role of NKG2D Signaling; Implications in Vitiligo and Melanoma | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 | $407,770 | September 18, 2023 | August 31, 2025 | GUEVARA-PATINO, JOSE ALEJANDRO | reporter.nih.gov |
| Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade | NIH | National Cancer Institute | 2021 | $393,450 | August 28, 2017 | July 31, 2024 | BEG, AMER AZIZ | reporter.nih.gov |
| H3 histone oxidation is a new posttranslational modification linking heavy metal-induced metabolic changes and oncegenic epigenetic reprogramming | NIH | National Institute of Environmental Health Sciences | 2025 | $372,660 | September 23, 2025 | October 31, 2028 | BONINI, MARCELO G. | reporter.nih.gov |
| Integrative analysis to identify genomic biomarkers in HPV positive oral cancer | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2024 | $337,000 | May 1, 2023 | April 30, 2025 | TENG, MINGXIANG | reporter.nih.gov |
| Libre Del Cigarrillo: Development of an mHealth Smoking Cessation App to Extend Reach of a Validated Smoking Cessation Intervention for Spanish-speaking Smokers | NIH | National Cancer Institute | 2025 | $316,873 | April 1, 2025 | March 31, 2028 | SIMMONS, VANI N | reporter.nih.gov |
| Development of a Quality of Life Decision-Making Model for Older Patients with Acute Myeloid Leukemia | NIH | National Institute of Nursing Research | 2021 to 2022 | $315,784 | May 4, 2020 | April 30, 2024 | TINSLEY, SARA | reporter.nih.gov |
| Spatial and Bayesian modeling methods for assessment of the tumor immune microenvironment and survival of women with ovarian cancer | NIH | National Cancer Institute | 2023 | $304,046 | May 1, 2023 | December 1, 2023 | FRIDLEY, BROOKE L | reporter.nih.gov |
| Radiomic biomarkers for clinical decision support that predict patient outcomes in serous ovarian carcinoma | NIH | National Cancer Institute | 2024 | $299,995 | September 13, 2024 | August 31, 2025 | PERES, LAUREN COLE | reporter.nih.gov |
| Employing functionalized fragment libraries to identify therapeutic agents for neurofibromatosis type 2 | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $289,588 | May 5, 2021 | December 31, 2022 | KISSIL, JOSEPH | reporter.nih.gov |
| Developing a culturally tailored mHealth symptom monitoring intervention to improve adherence to endocrine therapy among Black women with breast cancer | NIH | National Cancer Institute | 2023 | $284,604 | September 18, 2023 | August 31, 2024 | LEE, KIMBERLEY T | reporter.nih.gov |
| Utilizing Augmented Reality as an Adjunct for Smoking Cessation: Development and Initial Validation | NIH | National Institute on Drug Abuse | 2021 | $258,000 | May 1, 2019 | March 31, 2023 | VINCI, CHRISTINE | reporter.nih.gov |
| PFI-TT: Trustworthy Artificial Intelligence for the Volumetric Evaluation of Brain Tumors | NSF | Pathways for Translation Section | 2023 | $249,979 | August 15, 2023 | July 31, 2026 | Ghulam Rasool | nsf.gov |
| A clone's genomic stability as biomarker of its DNA-damage resilience | NIH | National Cancer Institute | 2021 | $248,992 | March 1, 2017 | July 31, 2022 | ANDOR, NOEMI | reporter.nih.gov |
| Mindfulness-based ecological momentary intervention for smoking cessation among cancer survivors | NIH | National Cancer Institute | 2023 to 2024 | $237,650 | April 1, 2023 | December 31, 2024 | YANG, MIN-JEONG | reporter.nih.gov |
| L-fucose-mediated enrichment of memory CD4+T cells and enhanced anti-melanoma immunity | NIH | National Cancer Institute | 2024 | $236,321 | February 1, 2024 | January 31, 2026 | LAU, ERIC KIRK | reporter.nih.gov |
| Cancer-related cognitive impairment: Real-time evaluation and assessment of long-term impact of treatment on young adult survivors (CRCI REALITY) | NIH | National Cancer Institute | 2022 to 2023 | $219,980 | July 1, 2022 | December 31, 2023 | TOMETICH, DANIELLE | reporter.nih.gov |
| Spontaneous humoral responses open opportunities for novel immunotherapies against human cancer | NIH | National Cancer Institute | 2022 to 2023 | $214,665 | December 16, 2021 | December 12, 2022 | BISWAS, SUBIR | reporter.nih.gov |
| Metabolic and molecular regulation of myeloid cell functions in brain cancer | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $211,285 | April 15, 2023 | December 1, 2023 | VEGLIA, FILIPPO | reporter.nih.gov |
| Modulating Glioblastoma Stem Cell Clonal Evolution Towards Therapeutic Responsiveness | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $205,875 | August 1, 2020 | July 31, 2023 | ETAME, ARNOLD | reporter.nih.gov |
| Ecology and Evolution of Breast Carcinogenesis | NIH | National Cancer Institute | 2021 | $201,634 | September 15, 2021 | December 7, 2021 | DAMAGHI, MEHDI | reporter.nih.gov |
| A framework to integrate live-cell imaging with single-cell sequencing and learn how cells adapt to new environments | NIH | National Cancer Institute | 2022 to 2023 | $179,479 | December 1, 2021 | November 30, 2024 | ANDOR, NOEMI | reporter.nih.gov |
| The COACH Study: A Framework for individualized COaching in young Adult Cancer survivors to encourage Healthy behaviors | NIH | National Cancer Institute | 2022 to 2023 | $173,941 | May 4, 2022 | April 30, 2024 | CROWDER, SYLVIA | reporter.nih.gov |
| A Federated Galaxy for user-friendly large-scale cancer genomics research | NIH | National Cancer Institute | 2022 | $171,200 | September 11, 2018 | August 31, 2024 | GOECKS, JEREMY | reporter.nih.gov |
| The role of HPV E1 in regulating the NRF2-KEAP1 pathway | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $168,500 | January 19, 2023 | December 31, 2024 | BINNING, JENNIFER | reporter.nih.gov |
| Health-related quality of life and patient reported outcomes among people living with HIV and cancer | NIH | National Cancer Institute | 2023 | $168,500 | August 16, 2023 | July 31, 2025 | ISLAM, JESSICA YASMINE | reporter.nih.gov |
| Targeting ULK3 for the treatment of triple negative breast cancer | NIH | National Cancer Institute | 2024 to 2025 | $168,500 | December 1, 2023 | May 31, 2026 | TAURO, MARILENA | reporter.nih.gov |
| Investigating lipid phenotype as a metabolic adaptation to microenvironmental stress | NIH | National Cancer Institute | 2024 to 2025 | $168,500 | March 22, 2024 | February 28, 2026 | PILLAI, SMITHA R | reporter.nih.gov |
| The oncogenic roles of alarmins and monocytes in triple negative myelofibrosis | NIH | National Cancer Institute | 2025 | $157,248 | September 1, 2025 | August 31, 2028 | VINCELETTE, NICOLE | reporter.nih.gov |
| SAMBAI - Establishing a comprehensive assessment of contributors to cancer inequities across the African diaspora | NIH | National Cancer Institute | 2024 | $142,189 | May 1, 2024 | April 30, 2026 | CARSON, TIFFANY LASHAUN | reporter.nih.gov |
| Mechanisms of dormant breast cancer cell communication with their environment | NIH | National Cancer Institute | 2025 | $123,182 | July 17, 2025 | June 30, 2027 | DRAPELA, STANISLAV | reporter.nih.gov |
| Targeting antioxidant vulnerabilities in KEAP1/NRF2 mutant NSCLC | NIH | National Cancer Institute | 2022 | $113,414 | September 1, 2022 | August 31, 2023 | JIANG, CHANG | reporter.nih.gov |
| Dual E3 ligase function of TRIM25 in modulating innate immunity | NIH | National Institute of General Medical Sciences | 2024 | $110,335 | May 1, 2024 | April 30, 2025 | SMALLEY, TRACESS | reporter.nih.gov |
| The importance of CD4+ tumor-infiltrating lymphocytes (TIL) in adoptive cell transfer | NIH | National Cancer Institute | 2021 to 2022 | $78,212 | March 1, 2020 | February 28, 2023 | HALL, MACLEAN | reporter.nih.gov |
| I-Corps: Detecting Performance Degradation and Failures of Deep Neural Networks in Cancer Imaging | NSF | Translational Impacts | 2023 | $50,000 | March 15, 2023 | August 31, 2024 | Ghulam Rasool | nsf.gov |
| 26th Annual Meeting of the PanAmerican Society for Pigment Cell Research | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $25,036 | August 15, 2025 | July 31, 2026 | SMALLEY, KEIRAN | reporter.nih.gov |
| Development and Validation of a Patient-Reported Measure Assessing Chimeric Antigen Receptor (CAR) T-Cell Therapy-Related Side Effects | NIH | National Cancer Institute | 2022 | $1 | March 8, 2022 | March 9, 2022 | BARATA, ANNA | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2026 | 0 | $0 | 1 | $450,000 |
| 2025 | 84 | $56,455,172 | 0 | $0 |
| 2024 | 104 | $55,778,607 | 0 | $0 |
| 2023 | 113 | $56,787,236 | 3 | $749,979 |
| 2022 | 112 | $55,738,189 | 0 | $0 |
| 2021 | 91 | $48,547,080 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 4 awards here | |
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | PA-24-194 | NIH | May 7, 2027 | Not listed | Notice number printed on 1 award here | |
| NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) | PA-25-080 | NIH | September 7, 2027 | Not listed | Notice number printed on 1 award here | |
| NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) | PAR-27-089 | NIH | 93.396 | November 2, 2026 | Not listed | Same assistance listing 93.396 as 46 awards here |
| NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) | PAR-27-088 | NIH | 93.396 | November 20, 2026 | Not listed | Same assistance listing 93.396 as 46 awards here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.396 | December 4, 2026 | Not listed | Same assistance listing 93.396 as 46 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.396 | January 7, 2027 | $375,000 | Same assistance listing 93.396 as 46 awards here |
| Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional) | PAR-25-221 | NIH | 93.396 | January 7, 2027 | Not listed | Same assistance listing 93.396 as 46 awards here |
| Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed) | PAR-27-009 | NIH | 93.396 | January 25, 2027 | Not listed | Same assistance listing 93.396 as 46 awards here |
| Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed) | RFA-CA-28-013 | NIH | 93.396 | February 9, 2027 | $700,000 | Same assistance listing 93.396 as 46 awards here |
| New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional) | PAR-25-272 | NIH | 93.396 | May 7, 2027 | Not listed | Same assistance listing 93.396 as 46 awards here |
| New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional) | PAR-25-279 | NIH | 93.396 | May 7, 2027 | Not listed | Same assistance listing 93.396 as 46 awards here |
| Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | RFA-CA-28-003 | NIH | 93.396 | June 11, 2027 | $600,000 | Same assistance listing 93.396 as 46 awards here |
| Successor-in-Interest (Type 6 Parent Clinical Trial Optional) | PA-24-253 | NIH | 93.396 | July 17, 2027 | Not listed | Same assistance listing 93.396 as 46 awards here |
| Investigator-Focused Award (Parent R35) | PAR-28-037 | NIH | 93.396 | October 4, 2027 | Not listed | Same assistance listing 93.396 as 46 awards here |
| Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) | RFA-CA-27-019 | NIH | 93.396 | October 19, 2027 | $300,000 | Same assistance listing 93.396 as 46 awards here |
| NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) | PA-25-301 | NIH | 93.396 | January 7, 2028 | Not listed | Same assistance listing 93.396 as 46 awards here |
| NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) | PA-25-304 | NIH | 93.396 | January 7, 2028 | Not listed | Same assistance listing 93.396 as 46 awards here |
| NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) | PA-25-306 | NIH | 93.396 | January 7, 2028 | Not listed | Same assistance listing 93.396 as 46 awards here |
| Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) | PAR-24-311 | NIH | 93.396 | January 7, 2028 | $500,000 | Same assistance listing 93.396 as 46 awards here |
Topics of its NIH awards
- Cancer
- Genetics
- Clinical Research
- Rare Diseases
- Biotechnology
- Prevention
- Immunotherapy
- Orphan Drug
- Human Genome
- Cancer Genomics
- Behavioral and Social Science
- Translational Research
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.